Document Detail


Pharmacotherapy of acute coronary syndrome: the ACUITY trial.
MedLine Citation:
PMID:  19191676     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Bivalirudin, a direct thrombin inhibitor, has unique attributes including predictable pharmacokinetics, a reduction in bleeding complications and avoidance of heparin induced thrombocytopenia. OBJECTIVE: We critically review the role of bivalirudin in the management of patients with acute coronary syndrome in light of the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. METHODS: Data from the ACUITY trial was critically reviewed along with other contemporary data. RESULTS/CONCLUSION: In the ACUITY trial, bivalirudin monotherapy was associated with rates of ischemic events that were noninferior to those associated with heparin plus glycoprotein IIb/IIIa inhibition, but was associated with a significantly reduced incidence of major bleeding. Bivalirudin seems to be an attractive antithrombotic agent in patients with acute coronary syndrome undergoing early invasive management.
Authors:
Debabrata Mukherjee; Kim A Eagle
Related Documents :
10598366 - Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments...
15800226 - Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.
21736726 - The relationship between inotrope exposure, six-hour postoperative physiological variab...
8542866 - Advances in antithrombotic drug therapy for coronary artery disease.
16423666 - Risk assessment in patients with depressed left ventricular function after myocardial i...
24338536 - Exendin-4 attenuates myocardial ischemia and reperfusion injury by inhibiting high mobi...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  10     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-04     Completed Date:  2009-05-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  369-80     Citation Subset:  IM    
Affiliation:
Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S. Limestone Street, 326 Wethington Building, Lexington, KY 40536-0200, USA. Mukherjee@uky.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*,  therapy
Angioplasty, Transluminal, Percutaneous Coronary
Anticoagulants / therapeutic use
Drug Therapy, Combination
Fibrinolytic Agents / adverse effects,  therapeutic use*
Heparin / therapeutic use
Hirudins / adverse effects
Humans
Peptide Fragments / adverse effects,  therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Randomized Controlled Trials as Topic
Recombinant Proteins / adverse effects,  therapeutic use
Thrombin / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Hirudins; 0/Peptide Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin; EC 3.4.21.5/Thrombin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacotherapy of patients with schizophrenia and substance abuse.
Next Document:  Tuberculosis pharmacotherapy: strategies to optimize patient care.